NASDAQ$ESTA
Establishment Labs Holdings Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Establishment Labs reported record fourth quarter revenue and progress in key strategic initiatives.
Establishment Labs reported a strong fourth quarter with record revenue of $35.3 million, a 31.0% increase year-over-year. Gross profit margin improved to 68.6%. The company provided 2022 revenue guidance of $155 million to $165 million, representing growth of 22% to 30%.
- Fourth quarter worldwide sales reached $35.3 million, a 31.0% increase year-over-year.
- Gross profit for the fourth quarter was 68.6% of revenue, compared to 54.3% for the same period in 2020.
- The company launched Motiva Flora® tissue expander in Europe and CE mark countries.
- 2022 revenue guidance of $155 million to $165 million, an increase of 22% to 30% over 2021.
Headline financials
Revenue & EPS history
Establishment Labs · Revenue · Quarterly
$35.3M
Forward guidance
Establishment Labs anticipates another strong year in 2022 with revenue between $155 million and $165 million.
Tailwinds
- Strong growth across all areas of the business.
- Launch of Motiva Flora® tissue expander and Aesthetic BreastRecon® program.
- Introduction of JOY™ and Ergonomix2®.
- Progress with Motiva MIA®.
- Regulatory and commercial timelines to begin selling Motiva implants in the U.S. and Chinese markets are progressing as planned.
Headwinds
- Operating losses and investments in facility expansion impacted cash balance.
- Increased operating expenses due to normalized spending levels.
- Increased SG&A expenses due to personnel costs and marketing expenses.
- Net loss from operations for the fourth quarter was $9.4 million.
- Cash decreased $31.1 million from December 31, 2020 and $11.2 million from the prior quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.5%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
56%
18 / 32 earnings
Positive
+22.5%
Q3 2025
Best reaction
-26.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -4.3% | +2.9% | |
| Q4 2025 | -1.9% | +5.0% | -20.1% | |
| Q3 2025 | +22.5% | +37.0% | +43.2% | |
| Q1 2025 | +4.9% | +5.1% | +14.2% | |
| Q4 2024 | +17.9% | +28.1% | +12.1% | |
| Q3 2024 | -5.2% | -13.2% | -10.0% | |
| Q2 2024 | +3.4% | +20.6% | +23.5% | |
| Q1 2024 | +5.4% | +4.2% | -10.8% | |
| Q4 2023 | +15.1% | +19.6% | +28.2% | |
| Q3 2023 | -26.0% | -36.1% | -31.7% | |
| Q2 2023 | -8.4% | -12.0% | -12.2% | |
| Q1 2023 | +1.8% | -1.6% | -1.9% | |
| Q4 2022 | +7.2% | +10.3% | +0.3% | |
| Q3 2022 | -7.7% | +11.1% | +27.1% | |
| Q2 2022 | -3.0% | +1.3% | -0.4% | |
| Q1 2022 | -10.5% | -10.1% | +2.3% | |
| Q4 2021 | +3.3% | +1.6% | +11.5% | |
| Q3 2021 | -10.6% | -14.3% | -15.2% | |
| Q2 2021 | +6.0% | -3.7% | -3.1% | |
| Q1 2021 | -0.6% | -1.8% | +8.9% | |
| Q4 2020 | +0.4% | -6.8% | +9.5% | |
| Q3 2020 | +8.9% | -0.4% | +22.6% | |
| Q2 2020 | +6.2% | +7.3% | +9.3% | |
| Q1 2020 | +2.9% | +0.5% | +15.3% | |
| Q4 2019 | +4.5% | -16.4% | +0.4% | |
| Q3 2019 | -0.3% | +0.5% | +7.8% | |
| Q2 2019 | -5.2% | -10.6% | -10.2% | |
| Q1 2019 | +1.5% | -0.3% | -15.9% | |
| Q4 2018 | -1.9% | -4.9% | -15.2% | |
| Q3 2017 | +10.3% | +4.5% | -6.2% | |
| Q3 2018 | +10.3% | +4.5% | -6.2% | |
| Q2 2018 | -2.7% | -2.9% | -3.4% | |
| Q4 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro